drugset / Trial / NCT01618916
A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
RandomizedParallel-groupDouble-blindBasic science
Summary
This is a phase 1 study in otherwise healthy participants with high LDL cholesterol. Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body will be evaluated. Participants will participate in the study for approximately 3 months not including screening. Screening is required within 42 days prior to the start of the study.
Timeline
- Start
- 2012-06
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FROVOCIMAB | Monoclonal antibody | 1 mg/kg | Subcutaneous |
| Subject | FROVOCIMAB | Monoclonal antibody | 3 mg/kg | Subcutaneous |
Indications
No indication recorded.